Engineering the Next Generation of CAR T Therapy:
Dual target strategy; in vivo innovation
Pipeline
Tempest is a clinical-stage CAR-T company building the future of in vivo CAR-T therapy with broad potential benefit for patients with autoimmune diseases or cancer